ArticleBreast care (Basel, Switzerland)2021

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients.

Christoph Suppan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.